This study will investigate disparities in neurocognitive impairment (NCI) among Hispanics/Latinos/as/x (henceforth Hispanics) living in the US-Mexico borderland of California or in North Carolina with Parkinson's Disease (PD) and determine mechanisms underlying these disparities. NCI is an important aspect of the clinical course of PD, particularly among Hispanics, who have increased prevalence of dementia. Among the many potential factors driving this disparity, the investigators chose to focus on a modifiable risk factor to which Hispanics are particularly vulnerable, and that has been linked to increased NCI, namely cardiovascular (CVD) risk (e.g., diabetes, hypertension, obesity).
The proposed study will use a cross-sectional design to determine the presence of NCI in 120 persons with PD (age 40+), living in the US-Mexico borderland of California or in North Carolina, including 60 Hispanics and 60 non-Hispanic Whites. All participants will complete comprehensive neuromedical and neuropsychological evaluations, a blood draw and assessments of socio-cultural factors (e.g., health literacy, access to care, acculturation, bilingualism, discrimination, socioeconomic status). Using these data we will examine the extent to which CVD risk (e.g., diabetes, hypertension, obesity), PD severity and social determinants of health drive NCI among Hispanics with PD. The present proposal will capitalize on the infrastructure and expertise available at Duke University and will follow a community-based participatory research approach to complete the proposed study aims.
Study Type
OBSERVATIONAL
Enrollment
40
All participants will complete comprehensive neuromedical and neuropsychological evaluations, a blood draw and assessments of socio-cultural factors (e.g., health literacy, access to care, acculturation, bilingualism, discrimination, socioeconomic status).
UC San Diego
La Jolla, California, United States
Duke University
Durham, North Carolina, United States
Language (Letter Fluency)
Time frame: Day 1 (day of enrollment)
Language (Animal Fluency)
Time frame: Day 1 (day of enrollment)
Language (Vegetable Fluency)
Time frame: Day 1 (day of enrollment)
Language (Multilingual Naming Test)
Time frame: Day 1 (day of enrollment)
Speed of Information Processing
Trail Making Test A
Time frame: Day 1 (day of enrollment)
Speed of Information Processing
WAIS-III Digit Symbol
Time frame: Day 1 (day of enrollment)
Speed of Information Processing
WAIS-III Symbol Search (Wechsler Adult Intelligence Scale)
Time frame: Day 1 (day of enrollment)
Attention/Working Memory
PASAT-50 (Paced Auditory Serial Addition Test)
Time frame: Day 1 (day of enrollment)
Attention/Working Memory
Number Span
Time frame: Day 1 (day of enrollment)
Executive Function
Trail Making Test B
Time frame: Day 1 (day of enrollment)
Executive Function
WCST-64 (Wisconsin Card Sorting Test)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 1 (day of enrollment)
Verbal Learning and Memory
Hopkins Verbal Learning Test-Revised
Time frame: Day 1 (day of enrollment)
Verbal Learning and Memory
Craft Story Learning \& Recall
Time frame: Day 1 (day of enrollment)
Visual Learning and Memory
Brief Visuospatial Memory Test - Revised, Benson Figure Delay
Time frame: Day 1 (day of enrollment)
Visual-Spatial skills
Benson Figure Copy
Time frame: Day 1 (day of enrollment)
Everyday Functioning
Modified Lawton-Brody Instrumental Activities of Daily Living questionnaire
Time frame: Day 1 (day of enrollment)
Diagnosis of MCI/dementia in PD
Objective presence of MCI and dementia in PD will be determined via comprehensive diagnostic criteria
Time frame: Day 1 (day of enrollment)
diabetes mellitus
fasting plasma glucose \>126 mg/dL, an HbA1c \>6.5%, or use of antihyperglycemic medications
Time frame: Day 1 (day of enrollment)
hypercholesterolemia and dyslipidemia
total cholesterol \>240 mg/dL, LDL cholesterol \>160 mg/dL, or HDL cholesterol \<40 mg/dL or on cholesterol-lowering medication
Time frame: Day 1 (day of enrollment)
hypertension
systolic blood pressure \>140 mm Hg, diastolic blood pressure \>90 mm Hg, or on antihypertensive medication
Time frame: Day 1 (day of enrollment)
current cigarette smoking
Self-report
Time frame: Day 1 (day of enrollment)
obesity
BMI of \>30.0
Time frame: Day 1 (day of enrollment)
Parkinson's disease severity
Movement Disorders Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time frame: Day 1 (day of enrollment)